The company is dedicated to the development, in/out-licensing and commercialization of innovative pharmaceutical products for the digestive system.

Tillotts successfully markets its own products for the treatment of irritable bowel disease, as well as in-licensed products, in around 65 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world.